Ampio Fails To Meet Primary Endpoint In Osteoarthritis Trial
April 20, 2015 at 19:24 PM EDT
Shares of Ampio tumble 66% after the company reported that it failed to meet the primary endpoint in the Phase 3 "Stride" study in patients with osteoarthritis.
